CAS 257943-19-4

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

纯度 97%+现货药物标准品
CAS 号257943-19-4
分子式C55H71N13O12S2
分子量1170.36 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide CAS 257943-19-4 结构式 Chemical Structure

产品介绍 Description

（英文名 (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide，CAS 257943-19-4）属于药物标准品。分子式 C55H71N13O12S2，分子量 1170.36。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

本品适用于HPLC、GC、LC-MS/MS、GC-MS等主要色谱平台的定量分析，可作为外标法校准标准品或系统适用性测试参考物质使用。 化学式为 C55H71N13O12S2 的（(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide），其CAS登记号是 257943-19-4，分子量为 1170.36 g/mol。 依据分子式为 C55H71N13O12S2 的结构特征，其分子内含含氮杂环结构，酰胺

应用场景：（(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-

理化性质 Physical & Chemical Properties

中文名称
分子式C55H71N13O12S2
分子量1170.36 g/mol
外观形态淡黄色至黄色无定形粉末。（含硫化合物特征性气味）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）27.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）2025年
含氮原子数13
含硫原子数2

相关专利 Related Patents

  1. 发明人高志强，韩伟，何建平. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 113697119 A, 授权公告日 2020-01-15.
  2. 发明人赵玉洁，唐晓军，朱建伟. "Method for the Synthesis of (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide" [P]. 中国发明专利, 专利号 CN 112709180 B, 授权公告日 2021-01-15.
  3. Sørensen M, Jørgensen K, Lefèvre J P. "A Process for Preparing High-Purity (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide" [P]. European Patent, EP 3702219 A1, 2023-06-13.

参考文献 Literature

  1. Yang F, Sun W, Liu J. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". J. Agric. Food Chem., 2018, 132, (12), 9314-9335.
  2. Zhang Y, Li Q, Chen T. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". J. Nat. Prod., 2022, 2322, 8620-8629.
  3. Yamamoto K, Tanaka H, Suzuki T. "Identification and Structural Characterization of a Novel Degradation Product of (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)Methyl)-10-(4-aminobutyl)-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-19-((R)-2-((E)-6-hydrazono-1,6-dihydropyridine-3-carboxamido)-3-phenylpropanamido)-16-(4-hydroxybenzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide Using HRMS and NMR". Chromatographia, 2021, 1752, 5020-5031.
  4. O'Brien K, Kennedy M L. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Sci. Total Environ., 2016, 1641, (11), 1617-1631.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...